27 Aug 2020
Intravacc’s candidate RSV vaccine demonstrates safety in phase I trial
By Staff Writer
Intravacc has announced, in the medical journal Vaccine, a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The vaccine showed excellent induction of immunogenicity after nasal administration to healthy adult volunteers (18-50 years). In addition, the Live Attenuated Vaccine (LAV), constructed with reverse genetics, appears to be safe and well-tolerated. Intravacc...